What is known:
INTRODUCTION
The global incidence of Crohn's disease (CD) has steadily risen over the past few decades, especially among pediatric patients (1) . Large efforts are being made to identifying novel non-invasive biomarkers not only to monitor disease severity but also to predict therapeutic response in CD patients (2, 3) .
Genome-wide association studies have identified a variety of risk loci within genes important for the maintenance of homeostasis with our commensal gut microbiota (4) . In this regard, several studies in pediatric CD patients have described a state of microbiome 'dysbiosis', with varying claims about disease-promoting or -ameliorating bacterial taxa (5) (6) (7) and about differences in bacterial diversity (8) . Previous work showed that the magnitude of antibiotic effects on the microbiota differs among individuals, and that some taxa show interindividual variation in the response to a single antibiotic treatment (9) . Similarly, several trials in adult CD found, in general, a benefit of antibiotic treatment, but with very heterogeneous results for the use of metronidazole, quinolones, and rifaximin (10) .
The goal of this study was to evaluate the impact of metronidazole (MET) and the combination of metronidazole and azithromycin (MET+AZ) on the intestinal microbiota of pediatric CD patients. We show that both antibiotic regimens led to a decrease in gut microbiota diversity, but also exerted a treatment-specific impact on the microbiota. Of note, we show that these two antibiotic regimens produced distinct alterations in microbiota structure associated with disease remission. We used machine-learning techniques to identify microbiota composition-based signatures associated with antibiotic treatment that might enable monitoring of disease and guide clinical decision making.
METHODS

Study Design
Seventy-four CD patients (age 5-18 years) were enrolled at 11 pediatric gastroenterology clinical sites in an investigator-blinded randomized controlled trial comparing the efficacy of MET+AZ versus MET therapy for the treatment of children with mild to moderate active CD (10 < Pediatric Crohn's Disease Activity Index (PCDAI) ≤ 40) (National Institutes of Health NCT01596894). A complete description of the study design, laboratory and analysis methods, and primary outcomes was published previously (11) . The treatment protocol was adapted from a report by Levine and Turner (12) . Patients were enrolled in one of the two treatment arms with 1:1 randomization, although 11 subjects with lack of response to MET therapy received openlabel azithromycin between weeks 4 and 8. These MET/MET+AZ subjects were treated as a separate group for analyses involving time points after week 4. Furthermore, 4 patients in the MET group, 5 patients in the MET+AZ group and 1 patient in the MET/MET+AZ group received steroids or biologics after week 4 at their physician's direction due to inadequate response. Both MET and MET+AZ groups discontinued antibiotics after week 8, while the MET/MET+AZ group maintained their regimen to complete a total of 8 weeks. Disease activity was determined at weeks 0, 4, 8 and 12 using the PCDAI, when stool samples were collected for microbiota analysis. Clinical remission was defined as PCDAI < 10. All patients provided written informed consent, or assent when required, prior to participation. The study was conducted according to the principles of the Declaration of Helsinki.
Microbiota Analysis
Stool samples were collected and frozen on site at -20°C and then shipped to a central laboratory and stored at -80°C until further processing. DNA was extracted from ~200 mg stool using the QIAGEN DNeasy PowerSoil HTP 96 Kit (Cat #12955-4) following the manufacturer's instructions, including a 2 x 10 minute bead-beating step using the Retsch 96 Well Plate Shaker at speed 20. The V4 region of the 16S rRNA gene was amplified using forward primer 515F (5′-8 GTGCCAGCAGCCGCGGTAA-3′) with an error-correcting barcode and 806R (5′-GGACTACCAGGGTATCTAAT-3′) (13) . PCR products were then purified, pooled in equimolar concentrations, and sequenced on three 2 x 300 Illumina MiSeq paired-end runs using reagent kit v3.
Raw reads were demultiplexed using the QIIME command split_libraries_fastq.py (QIIME version 1.9.1) and then quality trimmed using the DADA2 pipeline (dada2 version 1.1.1) in R (R version 3.2.4) (14) . Briefly, forward reads were truncated to 220 bp, and reverse reads to 150 bp, and quality filtered with settings maxN=0, maxEE=2, truncQ=2. Following quality trimming, amplicon sequence variants (ASVs) were inferred using the DADA2 pipeline. Taxonomy was assigned to each ASV using the RDP classifier and the SILVA 16S rRNA database (SILVA nr version 132), and a phylogenetic tree was built from the ASVs using the phangorn R package (phangorn version 2.4.0). The ASV table, patient sample data, taxonomy assignments, phylogenetic tree, and ASV sequences were then bundled into a single phyloseq data object for further plotting and statistical analysis (phyloseq version 1.24.2) (15).
Faith's Phylogenetic Diversity was calculated using the R package picante (picante version 1.7), and distance calculations and ordination plots were built using the phyloseq package. Hierarchical clustering of ASVs was performed using the hclust function in the stats R package (stats version 3.5.1). Differential abundance tests were carried out using the DESeq2 R package (DESeq2 version 1.20.0).
Random Forest Modeling
Machine learning analyses were performed using the caret and randomForest R packages A Random Forest model was constructed on all pre-antibiotic (week 0) microbiota data, as well as on clinical data, including sex, age, disease duration, tissue involvement (Paris classification), baseline immunomodulators, baseline CRP and PCDAI to predict disease state (remission or non-remission) at week 4 in both treatment groups combined. In order to increase the number of shared features found across samples and decrease the noise among closelyrelated bacterial taxa, ASVs were agglomerated based on their cophenetic distance in the phylogenetic tree at the h = 0.3 level. These numbered ASV clusters were also labeled by the number of ASVs in the cluster, as well as the genus that was assigned to the majority of the ASVs within the cluster. If >50% of the ASVs within a cluster were not assigned to a single genus, the same majority rule was used iteratively at higher taxonomic levels. Models were constructed and tested as described above. Abundance was normalized using variance stabilizing transformation (vst).
Amplicon sequencing data are available at SRA (project ID pending). A detailed description of this analysis, along with all analysis code and raw data used to go from sequences to final figures, is available at the Stanford Digital Repository (purl.stanford.edu/XXX) and as Supplementary Material.
RESULTS
Clinical Outcomes
A total of 67 subjects from 9 sites provided stool samples for microbiome analysis and are included in the present study (Table 1) . Of this group, 36 children were randomly assigned to receive MET, and 31 received MET+AZ ( Fig. 1a ). 
Microbiota Response to Single and Combination Antibiotic Therapies
Antibiotics can strongly perturb the distal gut microbiota in an individual-specific manner (16) ; individualized responses might explain some of the observed heterogeneity in disease progression and dynamics.
We observed a profound shift in gut microbiota diversity and structure following antibiotic administration in most subjects. In the MET and MET+AZ treatment groups, alpha diversity decreased significantly (Wilcoxon test, P ≤ 0.01) ( Fig. 2a ). Diversity remained low in both groups at week 8, and rebounded towards its pre-antibiotic level by week 12, after discontinuation of antibiotics. Yet, only the MET group achieved a diversity level that was comparable to its Next, we examined the magnitude of the change in microbiota structure in response to antibiotics by calculating the median difference in unweighted UniFrac distance between samples from the same patient. While we found no significant difference in mean unweighted UniFrac distance between weeks 0 and 4 across treatment groups, the MET/MET+AZ group showed a significantly larger shift in community structure than the MET group between weeks 4 and 8, possibly reflecting the addition of azithromycin ( Fig. 2b) .
We then assessed the contribution of current antibiotic use, treatment group, and remission status to variation in the data using principal coordinates analysis (PCoA) based on unweighted Unifrac distances (17) . The use of antibiotics at the time of sample collection was a significant source of variation ( Fig. 2c ) (PERMANOVA with 1000 permutations, P < 0.001), as was specific treatment ( Fig. 2d ) (PERMANOVA, P < 0.001) and remission status (PERMANOVA, P < 0.01) ( Fig. 2e ).
In order to identify groups of bacterial taxa with distinct responses to the different antibiotic regimens, we performed differential abundance testing between samples from weeks 
Microbiota and Crohn's Disease remission
To better understand how antibiotics might influence microbiota structure and remission, we calculated pairwise Bray-Curtis dissimilarity scores for remission samples and compared those to the pair-wise scores for non-remission samples in each treatment group. Week 4 and 8 samples from patients in the MET group who were in remission at that time were significantly more similar to each other than they were to week 4 and 8 samples from patients who were not in remission at the time (Wilcoxon text, P ≤ 0.001) (Fig. 4a ). We observed no significant differences for samples from the MET+AZ group. Furthermore, we found that remission samples from weeks 4 and 8 formed distinct clusters reflecting treatment group (PERMANOVA, P ≤ 0.001), a pattern that was not observed for non-remission samples (Fig. 4b ).
Based on these observations, we sought to identify treatment-specific microbial indicators of CD remission. We used Random Forest modeling to predict whether a patient was in remission based on their microbiota structure at that time. First, we constructed a model .4006 ), and classified remission in the MET+AZ group with an AUC of 0.68 (95% CI, 0.4066, 0.6764; sensitivity, 0.3846; specificity, 0.8889; P = 0.9909) ( Fig. 5a ), but did not achieve statistical significance in either case. In order to test an alternative model that incorporated a greater number of non-remission samples, we constructed Model 2 with samples from week 0 as well; these samples represent an alternative non-remission state prior to antibiotic administration, but at the same time, these samples introduce antibiotic treatment as a confounding factor (Model 2, weeks 0, 4 and 8). Model 2 classified remission in MET patients with improved accuracy and an AUC of 0.879 (95% CI: 0.683, 0.9877; sensitivity: 0.7778; specificity: 1.000; P < 0.001) and remission in the MET+AZ group with a lower AUC of 0.695 (95% CI: 0.5038, 0.7156; sensitivity: 0.20513; specificity: 0.93878; P = 0.1672) ( Fig. 5a ). Models 1 and 2 each assigned importance scores to each ASV based on the increase in model prediction error when that feature was randomly permuted while all others were left unchanged. The 10 most important ASVs in each model are displayed in Fig. 5b . The most important ASV for both models was ASV 291 (Lactobacillus) (Fig 5b) . The ASVs with high importance scores had different abundances in pre-antibiotics, remission, and non-remission samples. Compared to their relative abundances in pre-antibiotic samples, we observed a large increase in ASV 291 (Lactobacillus), ASV 60 (Klebsiella) and ASVs 2 and 154 (both Bifidobacterium), specifically in remission samples (Fig. 5c ). In agreement with the results shown in Fig. 3 . we observed an increase in abundance of ASVs 7 and 61 (both Enterococcus) from the pre-antibiotic state, but no discrepancy between remission and no-remission samples.
ASVs that decreased in remission samples, but not in non-remission samples, included ASV 16 (Fusicatenibacter saccharivorans) and ASV 24 (Dorea longicatena).
Next, we were interested in whether there were microbial signatures present prior to antibiotic administration that would predict remission after treatment. Although not statistically significant, pre-antibiotic samples from MET subjects who were in remission at week 4 trended towards higher alpha diversity (Supplemental Fig. 1a ), a pattern reported in other predictionfocused studies (27, 28) . Due to the limited number of pre-antibiotic samples available, we combined samples from both treatment groups, and information on each subject's age, sex, disease duration, tissue involvement, and the current disease state. Unfortunately, we still were not able to construct a robust model (AUC = 0.8; 95% CI: 0.4099, 0.8666; sensitivity, 0.8; specificity, 0.5; P = 0.24) (Supplemental Fig. 1b ). Furthermore, we identified ASV clusters with higher mean abundance in pre-antibiotic samples of subjects that went on to achieve remission, such as Cluster 8 (Peptostreptococcaceae), Cluster 24 (Alistipes), Cluster 23 (Clostridium sensu stricto) and Cluster 27 (Parabacteroides) (Supplemental Fig. 1c ). In contrast, for example, ASV Cluster 61 (Fusobacterium) was more abundant in pre-antibiotic samples of subjects who did not subsequently achieve remission, in accordance with other studies (7) .
Discussion
In this study, we determined the effects of MET-only and combination MET+AZ therapy on the gut microbiota in pediatric CD patients. We demonstrated a treatment-specific effect of both antibiotic regimens on microbiota structure, especially at the time of clinical disease remission.
We assessed the utility of microbiota signatures for classifying disease remission as well as the capacity of baseline (pre-antibiotic) microbiota structure to predict future treatment response.
In comparison to previous work, the strength of our study lies in the use of samples from a multinational cohort and from CD patients exclusively. Small cohort size is a common problem and has led to co-evaluation of samples from mixed patient populations with CD and ulcerative colitis, while recent data highlight the differences between those subtypes of IBD with respect to the microbiota (19) . Second, many previous studies have characterized the microbiota of patients based on one sample and time point (5, 7) , while the design of this study afforded an opportunity to monitor the microbiota before, during, and after treatment, which we believe is critical for identifying microbial signatures related to different clinical outcomes.
It is well established that antibiotic treatment creates an ecosystem-wide disturbance and decreases the overall diversity of the gut microbiome (20) . To our knowledge few studies have examined the effects of single versus combination antibiotics on the gut microbiome (21) .
While we observed a general decrease in diversity in response to antibiotics, our results also showed a distinct impact on microbiota structure and a decrease or increase of specific bacterial ASVs in each treatment group. This highlights the need to understand better the additive, antagonistic, synergistic, and non-linear effects of antibiotic treatments with regards to patient outcome. Despite different effects on the gut microbiota, the two treatments produced remission-compatible microbiota configurations.
Metronidazole is one of the most prescribed antibiotics in the treatment of pediatric CD, but to our knowledge, there has been no in-depth study of the effects of metronidazole treatment on the gut microbiota in humans to date. One study in mice, comparing the impact of metronidazole versus streptomycin on the microbiota and subsequent C. rodentium-induced colitis, observed treatment specific effects, not only on microbiota structure, but on gut mucosal immune responses as well (22) . In the absence of C. rodentium infection, metronidazole was found to decrease goblet cell expression of MUC2, thereby leading to a thinning of the inner mucus layer, which could be detrimental for intestinal homeostasis and promote chronic intestinal inflammation. Although this observation has not been confirmed in humans, it has important implications for the use of MET in IBD patients.
Recent studies reported superior outcomes for MET plus AZ as compared to MET alone (19, 20) . AZ penetrates multiple intestinal compartments, including the intestinal lumen, biofilms in the mucus layer, as well as macrophages (23, 24) , which would allow the targeting of various pathogens implicated in CD, such as adherent and invasive E. coli (AIEC) strains (25) (26) (27) . Also, genera such as Escherichia and Haemophilus have been associated with CD at disease onset in children (13) . Our observations of reduced abundances of ASV 4 (Escherichia/Shigella) in the MET+AZ group, and increased abundances in the MET group may reflect specific targeting of this taxon by azithromycin in our cohort. To be able to assess the presence of AIEC specifically, patient biopsies could be used in the future to access the mucosa-adherent or intracellular microbial constituents.
We also observed that some bacterial taxa such as Enterococcus, Streptococcus, Klebsiella, Bifidobacterium and Enterobacteriaceae increased in abundance during antibiotic treatment. This could be due to creation or expansion of nutritional and/or environmental niches during or after general community disturbance, or could indicate intrinsic or acquired antibiotic resistance. Our finding of increased abundances of Enterococcus ASVs in both treatment groups is concerning, as they possess multiple mechanisms for resisting antibiotics; their expansion could predispose patients to invasive infections (28, 29) .
Another important question is whether the microbiome itself might be used as a therapeutic agent for Crohn's disease, for example by administration of specific beneficial microbes as probiotics (30) . Our study identified multiple Lactobacillus ASVs that were important for the classification of clinical remission and that significantly increased during remission). Lactobacillus species are commonly used as probiotics and several in vitro and animal studies suggest that they have properties able to reduce inflammation in Crohn's Disease (31, 32) . In humans, clinical trials with Lactobacillus probiotics in CD patients have so far been unsuccessful (33, 34) , highlighting the need to understand not only the biology of Lactobacillus species but microbial community ecology.
Two recent studies predicted the success of biologics based on pre-treatment microbiota data in adult IBD patients (27, 28) . We also demonstrated that Random Forest models can be useful for microbiota-based classification and prediction. Our efforts in constructing useful classifiers for disease remission or prediction of treatment response to antibiotics draws attention to the importance and difficulties of obtaining sufficient numbers of samples.
In conclusion, there are several important implications to our findings. Our results suggest that there is no single antibiotic induced remission state, but that each regimen may impact the microbiome in an antibiotic-specific manner leading to remission. We showed that the classification of pediatric CD patients in antibiotic-associated clinical remission based on their microbiota structure is possible, although large sample sizes are required for accurate model construction. We demonstrated that classification and prediction models based on microbiota signatures may be another tool for monitoring disease and treatment response.
Moreover, they may also support the development and testing of more precise approaches for microbiome manipulation and could eventually lead to more effective management of CD and other inflammatory bowel disease. Significance of treatment group clustering was determined by PERMANOVA (adonis) with 1,000 permutations. Abundances were transformed using a variance stabilizing transformation (Bioconductor package vsn). SD standard deviation.
